UNIVEC and 11 Three launch RELIEFTA pain patch

UNIVEC, Inc. and 11 Three LLC said July 1, 2026, they are rolling out RELIEFTA™, a transdermal neuro-anesthetic pain patch built on patented SENDS™ nano-technology at the University of Maryland BioPark in Baltimore. The companies say the patch is designed to improve skin delivery and avoid systemic organ toxicities as it moves toward e-prescribing networks.

Why it matters: - RELIEFTA™ is being positioned as a non-systemic pain delivery option that aims to reduce the organ toxicity risks associated with some drug delivery methods. - The patch could matter for providers and patients looking for an alternative to traditional over-the-counter transdermal products that can suffer from poor absorption and premature peeling.

What happened: - UNIVEC, Inc. and manufacturing partner 11 Three LLC announced the rollout of RELIEFTA™, an advanced transdermal neuro-anesthetic pain patch. - The announcement was made July 1, 2026, from Baltimore. - The product is being developed and manufactured within the University of Maryland BioPark. - UNIVEC said RELIEFTA™ will transition into healthcare e-prescribing networks in the coming weeks. - For clinical data requests or institutional onboarding information, the companies direct readers to more information.

The details: - RELIEFTA™ uses 11 Three's patented SENDS™ platform, short for Self-Emulsifying Nano-Delivery System. - The SENDS™ nano-micellar engine temporarily fluidizes the skin's lipid junctions. - The formulation components then self-emulsify into sub-micron nano-micelles. - The delivery mechanism is designed to prevent compound crystallization, poor absorption, and premature peeling. - UNIVEC said the collaboration combines 11 Three's BioPark research footprint with UNIVEC's distribution infrastructure. - Dr. David Dalton, CEO of UNIVEC, said the launch is a critical step in the joint commercialization pathway. - Dalton said the companies are bringing a non-systemic delivery asset to providers and patients nationwide. - UNIVEC describes itself as a public health, regulatory, and distribution corporation with a nationwide footprint of 60,000 independent retail intersections. - 11 Three LLC describes itself as an advanced transdermal technology partner based at the University of Maryland BioPark in Baltimore. - 11 Three says it owns the patented SENDS™ platform and builds clinical-grade transdermal vehicles for targeted pain management.

Between the lines: - The BioPark setting signals a push to pair academic-clinical infrastructure with commercialization. - The emphasis on nano-delivery and non-systemic absorption suggests the companies are targeting a market gap between conventional patches and more invasive pain treatments. - The announcement focuses on platform capability and channel readiness, not on published clinical trial results.

What's next: - RELIEFTA™ is expected to move into e-prescribing networks in the near term. - Institutional onboarding and clinical data requests are expected to follow through 11 Three's contact channels. - The companies are likely to use the rollout to expand provider awareness and distribution reach.

The bottom line: - UNIVEC and 11 Three are taking a patented transdermal pain platform from development into commercial rollout, with RELIEFTA™ pitched as a more targeted alternative to legacy OTC patches.